Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Impact · against what's priced in

The $210 million voucher sale provides a concrete catalyst for RARE by monetizing an asset the market had not yet fully valued. This non-dilutive cash infusion directly addresses the company's high cash burn and reduces the immediate need for equity financing.

RARE+0.40: Challenges what's priced in
The price assumes: The value of the Priority Review Voucher received with FAYUVI, which provides a one-time cash windfall the market has not fully absorbed.
The agreement to sell the voucher for $210 million converts a theoretical asset into realized cash, supporting a valuation point the market had previously declined to price in.
What RARE's price assumes · Sep 22

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

biotech
RARE
fda
non dilutive funding
pharma
priority review voucher
rare disease

Search tags

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

What matters in this story

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

What matters in this story

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

How each ticker is affected

Track these names every morning.

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Xencor: Better Funding For Obexelimab

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Futura Medical plans 2027 Eroxon Intense launch after positive test

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

What matters in this story

Next reads from the same story arc

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

What matters in this story

Next reads from the same story arc

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

How each ticker is affected

Track these names every morning.

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Xencor: Better Funding For Obexelimab

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Futura Medical plans 2027 Eroxon Intense launch after positive test